Live attenuated Leishmania vaccines: a potential strategic alternative

• Authors: R. Silvestre , A. Cordeiro-da-Silva , A. Ouaissi
• Languages of publication: EN

Abstracts

EN

Leishmaniasis causes significant morbidity and mortality worldwide, constituting an important public health problem. Leishmania infections cause a wide spectrum of diseases, ranging in severity from spontaneously healing skin lesions to fatal visceral disease. Attempts to develop an effective vaccine to control leishmaniasis have been shown to be feasible, but no vaccine is in active clinical use. The ability to create genetically modified parasites by eliminating virulence or essential genes is considered a powerful alternative in the development of an effective protective vaccine. Here, recent findings related to genetically defined live attenuated Leishmania parasites as promising vaccine candidates are reviewed.

Keywords

EN

GMO; LEISHMANIA; LEISHMANIASIS; VACCINE

Discipline

• IMMUNOLOGY: IMMUNOLOGY

• Publisher: Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
• Journal: Archivum Immunologiae et Therapiae Experimentalis
• Year: 2008
• Volume: 56
• Issue: 2
• Pages: 123-126

Contributors

author

R. Silvestre

author

A. Cordeiro-da-Silva

author

A. Ouaissi

• Document Type: MINIREVIEW
• Publication order reference: Ali Ouaissi, INSERM, UMR 554, CNRS 5048, Centre de Biochimie Structurale, Montpellier, 29 rue de Navacelle, 34090, Montpellier Cedex, France